浩欧博(688656.SH)：脱敏药（MM09舌下喷雾剂）III期临床试验完成首批受试者入组

Core Viewpoint - The company has signed an exclusive strategic cooperation agreement with Inmunotek S.L. to introduce and sell the Oraltek® series of desensitization drugs in the Chinese market, addressing the needs of allergy patients and enhancing the development of the allergy diagnosis and treatment industry [1] Group 1: Strategic Cooperation - The company will exclusively introduce Inmunotek's Oraltek® series of desensitization drugs to the Chinese market [1] - This partnership aims to implement the company's new business in the domestic desensitization drug sector [1] Group 2: Clinical Trials and Regulatory Approvals - The company's wholly-owned subsidiary, Shanghai Haobio Pharmaceutical Co., Ltd., has successfully completed the first batch of subject enrollment for the Phase III clinical trial of the desensitization drug MM09 sublingual spray [1] - Three products related to cat hair, dog hair, and house dust mites have received the "clinical urgently needed imported drug approval" under the "Guangdong-Hong Kong-Macao Greater Bay Area" policy [1]